JPH0368513A - Patching agent - Google Patents

Abstract

PURPOSE:To obtain a patching agent capable of storing for a long period of time and having excellent lenitive and antiphlogistic action by using a saponified ethylene-vinyl acetate copolymer satisfying specific condition and a crystalline thermoplastic polymer as fiber material for base cloth of patching agent. CONSTITUTION:A saponified ethylene-vinyl acetate copolymer (A-polymer) containing 25-70mol% ethylene and having >=95% degree of saponification and a crystalline thermoplastic polymer (B-polymer) having >=150 deg.C melting point with excellent fiber forming property are subjected to conjugate spinning and resultant conjugate fiber is used as fiber material for base cloth. Then, the surface layer of fiber aggregate containing >=10% conjugate fiber in which >=60% of fiber peripheral length is occupied by the A-polymer is coated with vegetable oils dissolving non steroid-based lenitive and antiphlogistic agent having excellent percutaneous absorption properties to afford the aimed patching agent.

Description

DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to a patch that has excellent analgesic and anti-inflammatory effects without decreasing its medicinal efficacy even after long-term storage.

[Conventional technology]

Many inflammatory pain diseases, such as arthritis, endomyositis, and chrysalis, occur locally and relatively close to the body surface. Therefore, if it is possible to absorb nonsteroidal anti-inflammatory drugs transdermally and obtain higher drug distribution in the inflamed area than in the blood, it would be possible to achieve high local efficacy and prevent gastrointestinal disorders that often occur when applied systemically. It is expected to reduce side effects.

Currently, ointments containing non-steroidal anti-inflammatory drugs are being evaluated for their usefulness in the treatment of orthopedic diseases because they are safer than oral preparations and because they are easier to administer to the joints of the extremities. However, due to its formulation properties, ointments cannot be said to fully meet the objectives in terms of uniformity of dosage, stability of the formulation after administration, and persistence of drug efficacy.

Another preparation that is expected to have the same effect is a patch.

This is generally in the form of a poultice, which has an ointment applied to one side of the cloth, and has superior formulation stability, uniformity of dosage, and long-lasting medicinal efficacy compared to ointments. It is a formulation.

However, when conventional patches are stored for a long time in actual use, their medicinal efficacy often decreases compared to the initial state, and the medicinal effects often decrease during actual use. However, there was a problem in that the medicinal efficacy decreased significantly when the usage time became long. In particular, in recent years, synthetic fibers such as polyethylene terephthalate fibers have been increasingly used as base fabrics for pasting and opening, and the above-mentioned problems have often occurred.

[Problem that the invention seeks to solve]

Therefore, the object of the present invention is to obtain a patch that has excellent analgesic and antiinflammatory effects that do not reduce its medicinal efficacy even when stored for a long period of time. The present inventors have arrived at the present invention as a result of intensive studies on what kind of structure and what requirements should be adopted for a patch for such purposes.

[Means to solve the problem]

The present invention consists of a saponified ethylene-vinyl acetate copolymer (Polymer A) with an ethylene content of 25 to 70 moles and a degree of saponification of 95% or more, and a crystalline thermoplastic polymer with a melting point of 150°C or more that has fiber-forming properties. A vegetable oil in which a non-steroidal transdermal analgesic and anti-inflammatory agent is dissolved and dispersed in the surface layer of a fiber aggregate consisting of (B polymer) and containing 10% or more of composite fibers in which A polymer accounts for 60% or more of the fiber circumference. This is a patch that has excellent analgesic and antiinflammatory effects without decreasing its medicinal efficacy over time.

As the non-steroidal transdermal analgesic and anti-inflammatory agent used in the present invention, basically all drugs currently recognized to be effective as non-steroidal anti-inflammatory analgesics can be used. Especially among them, ketoprofen, indomethacin, flurpiprofen, methyl salicylate, diclofenac, ibuprofesa? which are effective drugs.

For example, to explain in detail a few of the above drugs, flurpiprofen has a prostagladein (
Prostaglandine) biosynthesis inhibitory effect, vascular hyperpermeability increase inhibitory effect, leukocyte migration inhibitory effect, protein thermal denaturation inhibitory effect, cell membrane stabilizing effect, and fradikinin (
It is believed that the inhibitory effect on the release of bradykinin (bradykinin) is involved, and it is thought that these effects work cooperatively in the inflamed area, resulting in powerful anti-inflammatory and analgesic effects. This transdermal nonsteroidal anti-inflammatory painkiller using flurpiprofen was approved on March 29, 1988, and three products are currently on the market: Atofeed 1, Zebolas, and Stavan. It has reached this point.

Indomethacin is also a non-steroidal anti-inflammatory and analgesic, and the current amount is recognized as an effective substance. The mechanism of action of indomethacin is similar to that of prostaglandine (prostaglandine), which inhibits biosynthesis, inhibits vascular permeability, inhibits leukocyte migration, inhibits protein thermal denaturation, stabilizes cell membranes, and bradykinin (prostaglandine). ), and these effects act cooperatively at the inflamed local area, making it a powerful anti-inflammatory,
It is thought that it exerts an analgesic effect. Since the manufacturing approval of indomethacin gel in 1980, it has been in the spotlight as it has been used as an oral formulation, injection formulation, and full-strength formulation. Indomethacin was released in March 1988.
It was approved on April 29th, and three products are currently on the market: ``Katlep,'' ``Idomeshin Kowa Bag,'' and ``Inside Pap.''

Another representative drug is ketoprofen, which is thought to have a similar mechanism of action to indomethacin, and is increasingly used. Ketoprofen was approved on March 29, 1988, and three types of products are currently on the market: "Morus,""Mirtax," and "Kefina."

Among the above non-steroidal transdermal analgesic and anti-inflammatory agents, only one type may be used, or two or more types may be used.

Usually, one type of drug is sufficient to exert its medicinal effect.

Generally, patches have a structure in which a mixture of drug and base is applied to a base fabric made of fiber aggregates, and a release paper is pasted on top of it, but in recent years, synthetic fibers such as polyethylene terephthalate have been used as the base fabric. Since it has become widely used, it has been observed that the medicinal efficacy of the patch often decreases when it is stored for a long period of time.

As a result of intensive research into the cause of this problem, the present inventors have found that a major factor lies in the base material applied together with the drug. The vegetable oils used to dissolve the drug are absorbed into the fibers while the patch is stored, and the amount of effective drug gradually decreases. I understand. Therefore, the present inventors have determined that in order to suppress such phenomena that have a negative effect on drug efficacy,
This study clarified what kind of material should be used as a fiber material.

The vegetable oils mentioned here are those that dissolve drugs,
A medium for applying to the surface of a fiber base fabric together with other base materials for adhesion to the skin, such as gelatin mixed with titanium oxide, and skin surface wetting agents such as glycerin. Avinis oil, amyris oil, angelica oil, amphrette seed oil, ylang-ylang oil, elemi oil, oakmoss oil, onitsha oil, origanum oil, orris oil, cassi oil, cananga oil, chamomile oil, kayafuchi oil,
Calamus oil, galbanum oil, guaiacus wood oil, grapefruit oil, costus oil, azalea oil, citronella oil, jasmine oil, ginger oil, sweet orange oil, styrax oil, spearmint oil, cedarwood oil, geranium oil, davana oil , tansy oil, turpentine oil,
Tuberose flower essential oil, neroli oil, pine oil, patchouli oil, mustard oil, vanilla oil, balsam cobaiba oil, balsam toru oil, balsam peru oil, harmarosa oil,
Hiritsubu oil, bitter almond oil, bitter orange oil,
Hiba oil, vetiver oil, peppermint oil, pennyroyal oil, perilla oil, bergamot oil, benzoin oil, boa oil
Rose oil, aromatic oil, mandarin oil, eucalyptus oil, lavandin oil, lavender oil, lemon oil, lemongrass oil,
Natural vegetable oils such as rose oil and rosemary oil, and synthetic compounds that imitate the main components of these natural vegetable oils, i.e. α
- Terpene hydrocarbons such as pinene, β-pinene, camphene, limonene, myrcene, β-caryophyllene, linalool, geraniol, nerol, citronellol, lavender oil, myrcenol, α-terpineol, Z-
Menthol, borneol, 7-ball, inbornylcyclohexanol, farnesol, nerolidol, santalol, cedrol, terpene alcohols such as baculi alcohol, benzyl alcohol, phenethyl alcohol, γ-phenylglopyl alcohol, cinnamon alcohol, anth alcohol , d-α-dimethylphenethyl alcohol, α-phenylethanol, β-phenylethyldimethylcarbinol, phenoxyethanol,
alcohol such as Patuchon, diphenyl ether isosafroeukenol, p-methylanisole, anethole, eugenol, ineugenol, methyleugenol, methylineugenol, benzylineugenol, safrole, insafrole, methyl-β-naphthyl ether, ethyl-β- Phenol and its derivatives such as naphthyl ether, hexenal, octanal, nonanal, decanal, undecanal, dodecanal, 2-methylundecanal, tridecanal, tetradecanal, hexadecanal, trans-2-hexenal, 2□6-nonajenal Aliphatic aldehydes such as citral, citronellal, hydroxycitronellal, perilaldehyde, citronellyloxyacetaldehyde, lyral, terpene aldehydes such as sinensal, benzaldehyde, phenylacetaldehyde, 3-phenylpropionaldehyde, cinnamaldehyde, α-A□ Lucinnamaldehyde, α-hexylcinnamaldehyde, anisaldehyde, cuminaldehyde, biperonal, cyclamenaldehyde, pt-7
Aromatic aldehydes such as thiru-α-methyldihydrocinnamaltehyde, vanillin, and pulbonal, acetals such as citral dimethyl acetal, citral diethylacecool, hydroxycitronellal dimethyl acecool, and phenylacetaldehyde dimethyl acetal;
2-heptanone, 3-octanone, 2-octanone, 2
- Aliphatic ketones such as undecanone, carvone, menthone,
Terpene ketones such as brevon, p-methylacetophenone, p-methoxyacetophenone, benzophenone, benzylideneacetone, anisylacetone, p-hydroxybenzylacetone, aromatic ketones such as 2-acetonaphthone, α-β-γ-ionone, α-n1 β-n1 γ-
n-methylionone, αβ-γ-isomethylionone, α
-β-γ-iron, α-β-damascenone, α-β-γ-
Damascon, theaspiran, theaspirone, ezran, rosefuran, nootkatone, α-vetivone, cis
- Jasmone, dihydrojasmone, methyl jasmonate, methyl dihydrojasmonate, jasmine lactone, maltol, cyclotene, furaneol, etc. cycloaliphatic ketones, cycloaliphatic nityl, cycloaliphatic lactones, muscone, civetone, cyclopentadecanone, cyclo Pentadecanolide, Ampretlide, Cyclohexadecanolide, Ethylene Brasilard, 12-Oxahexipdecanolide, 1
Macrocyclic ketones such as 1-oxahexadecanolide and 10-oxahexadecanolide, lactones, musk xylene,
Musk ketone, musk amp red, mosken, celestride, fantolide, tonalide, borachirylide, etc. synthetic musk, rose oxide, oxide ketone, linalool oxide, 1,8-cineole, bicyclodihydrohomofarnesyl oxide isokinetic ethers, indole, skatole, 6 -Methylquinoline, 7-methylquinoline, 6-ingrovirquinoline, 2-methyltetrahydroquinoline, 6-methyltetrahydroquinoline, 2
-inbutylthianol, 2-furylmethanethiol,
2-methylpyrazine, 2,5-dimethylpyrazine, 2,
3. Heterocyclic compounds such as 5-trimethylpyrazine, esters of aliphatic acids such as geranyl formate, benzyl formate, ethyl acetate, and geranyl acetate, methyl benzoate, isolamyl benzoate, ethyl anthate, methyl salicylate, methyl cinnamate, etc. It is a dangerous vegetable oil consisting of a mixture of esters of aromatic acids.

This will be explained by taking peppermint oil, which is typically used, as an example. Various polymers were made into films and tested for their permeability to menthol, the main component of peppermint oil. As a test method, various plastic films 1
A bag having a thickness of 5 to 25 μm was made into a 5×10 − pouch, filled with menthol 12, and sealed with an impulse sealer. Place each sachet in a 250° deodorized glass pin to detect the odor! The time was measured. As a result, polyethylene terephthalate, polycarbonate, polyethylene, etc. will start to smell in glass bottles within a week, whereas
It can be seen that the saponified film of ethylene-vinyl acetate copolymer has excellent barrier properties, with no odor perceptible even after two weeks or more. It can be said that the present invention was discovered by utilizing the oil-resistant property of the saponified product of this ethylene-vinyl acetate copolymer.

That is, an important point of the present invention is to use a saponified ethylene-vinyl acetate copolymer (hereinafter abbreviated as A polymer) as the fiber material for the base fabric on the application side. Although it is of course possible to make fibers using polymer A alone, the processability of the fiberization process is somewhat poor, the dimensional stability of the fibers, and the heat resistance when wet are slightly inferior.
We have decided to use a composite fiber obtained by composite spinning with another crystalline thermoplastic polymer with good fiber-forming properties and a melting point of 150° C. or higher (hereinafter abbreviated as B polymer).

In this case, if the A polymer occupies approximately 60 or more of the fiber circumference, the oil resistance effect against the vegetable oils will be exhibited, and it will be sufficiently effective to maintain the desired medicinal effect. I understand.

The saponified ethylene-vinyl acetate copolymer as component A has a high saponification degree of 95% or more and an ethylene content of 25 to 70 mol, that is, a vinyl alcohol component of 30 to 70 mol. The one with a reward of 75 moles is optimal.

If the content of the alcohol component in the polymer A becomes low, the oil resistance against vegetable oils will naturally decrease due to the decrease in hydroxyl groups (OH), making it impossible to obtain the desired durability of the desired medicinal effect. It's not a good shelter. If the content of the vinyl alcohol component is too high, the melt strength will decrease, and after composite spinning with component B, the stringiness will be poor, single yarn breakage, yarn breakage, etc. becomes more,
I don't like it. Furthermore, as an example, when polyester is used as component B, the heat resistance at the spinning temperature of 250 DEG C. or higher is also insufficient, which is also not appropriate. Therefore, it can be said that a fiber having a high saponification degree and a vinyl alcohol component content of 30 to 75 moles is suitable for obtaining the desired fiber.

Polymer A is produced by saponifying copolymerization of ethylene and vinyl acetate using a caustic powder, and the degree of saponification at this time is preferably 95 or higher. When the saponification degree decreases, not only does the crystallinity of the polymer decrease and the fiber physical properties such as strength decrease, but also the A polymer tends to soften, causing problems in the processing process and the resulting fiber structure. The texture of the object also deteriorates, making it unsuitable for shelter. Furthermore, oil resistance is also significantly reduced, resulting in a reduction in the desired effects of the present invention.

In the present invention, the B polymer having a melting point of 150°C or higher includes:
Any polymer having a melting point of 150"C or higher and good fiber forming properties may be used. Preferably, a polyester containing polyethylene terephthalate, polybutylene terephthalate, or polyhexamethylene terephthalate as a main component, or nylon 6 or nylon 66 Alternatively, it is desirably a polyamide containing nylon 12 as a main component.

Examples of the polyester include terephthalic acid, inphthalic acid, naphthalene 2,6-dicarboxylic acid, phthalic acid, α,β-(4-carboxyphenoxy)ethane,
, 4-cyclodiphenyl, aromatic dicarboxylic acids such as pentasodium sulfoinphthalate, or aliphatic dicarboxylic acids such as adipic acid, sebacic acid, or their esters, ethylene glycol, diethylene glycol, 1,4 butane Diol, 1.6 hexane diol, neopentyl glycol, cyclohexane 1.4-
A fiber-forming polyester synthesized from diol compounds such as dimethanol, polyethylene glycol, and polytetramethylene glycol, in which 80 moles or more of the constituent units are polyethylene terephthalate units, polybutylene terephthalate units, or polyhexamethylene terephthalate units. Preferably, the polyester is The polyester may also contain small amounts of additives, fluorescent whitening agents, stabilizers, UV light absorbers, etc.

In addition, polyamides include nylon 6, nylon 66,
It is a polyamide mainly composed of nylon 12, and may also be a polyamide containing a small amount of a tertiary component. These may contain small amounts of additives, fluorescent brighteners, stabilizers, etc.

Specific examples of cross-sectional shapes as composite forms of the composite fiber of the present invention are explained with drawings: a complete core-sheath type composite fiber as shown in Figure 1, a core with irregularly shaped core components as shown in Figures 2, 3, and 5. Sheath-type composite fibers, multifilamentary composite fibers as shown in Figure 4, eccentric core-sheath type composite fibers as shown in Figure 6, irregular cross-section core-sheath composite fibers as shown in Figure 7.10, and bonded type composite fibers as shown in Figure 8. Composite fibers, multilayer bonded conjugate fibers as shown in FIG. 9, modified multilayer bonded conjugate fibers as shown in FIG. 11, random conjugate fibers as shown in FIGS. 12 and 13 are also included. Figures 1 to 13 (
Component (a) is a saponified ethylene-vinyl acetate copolymer, and component (b) is a thermoplastic polymer with a melting point of 150°C or higher. It is desirable that component (a) polymer accounts for about 60% or more of the fiber cross-sectional circumference.

If it is less than 60%, as mentioned above, it is difficult to obtain the characteristics of a fiber base fabric for the application side that has good durability and medicinal effects, which is the objective of the present invention, so it is preferable! It's not right. The composite ratio of component A and component B is preferably in the range of 80:20 to 20:80 by weight. When the amount of component A becomes less than 20% by weight,
This is not desirable because the oil resistance to good vegetable oils, which is the object of the present invention, becomes insufficient. On the other hand, if the weight exceeds 80, process properties such as spinnability and stretchability will deteriorate, and the A rating will decrease, which is not preferable.

Next, a method for producing fibers used for the base fabric for the application side of the present invention will be briefly described. FIG. 14 schematically shows a spinning apparatus of the present invention.

One of the two melt extruders (1) has resin (4), and the other -
Part (2) is filled with resin CB) which has better spinnability than part (A). The polymer a melted and extruded by the extruder is accurately measured by a gear pump and sent to the spinning head. The two polymer streams are combined by a pack fitting installed in the head and then discharged through the spinneret.
rL fiberized.

The composite form of resin (B) was determined by considering performance such as medicinal performance, durability, and processability such as spinnability and stretchability. It has been found that any form that includes more than 60 parts is sufficient.

When kneading resins (A) and (B) to some extent as shown in FIGS. 12 and 13, a static mixer is used.

The spinning speed is 3 Q OQ m/m as with general fibers.
In or less, or 3000 to 5000 m/rn
Either in-high speed spinning may be performed. Polymer A may lack stringiness when used alone, but PET, PBT
By combining it with nylon, nylon, etc., even high-speed spinning can be performed without any problem. Depending on the composite resin or composite form, separation of the two resins may occur during stretching, so high-speed spinning may be effective in that case. If this is not the case, it is also possible to obtain a yarn with high strength by spinning at a normal spinning speed and ensuring stretching.

The obtained fibers are then formed into various fiber aggregate forms as required depending on the purpose. Although 100 or more of these composite fibers may be used to create a fiber aggregate, the effects of the present invention can also be obtained by mixing other fibers.

However, it is natural that the effect obtained will decrease as the blending ratio t and b of the composite fiber decreases, so it is preferable to maintain it at 10% or more.

The fiber aggregate may be in any form such as nonwoven fabric, knitted fabric, or woven fabric, but nonwoven fabric is optimal in terms of cost.

Next, the present invention will be specifically explained using examples.

[Example 1] Polymer A had a saponification degree of 99 and an ethylene content of 4.
A saponified product of 4 moles of ethylene-vinyl acetate copolymer was used, and polyethylene terephthalate with [η] 0.60 (intrinsic viscosity measured at 30°C with a solution of equal amounts of phenol and tetrachloroethane) was used as the B polymer. After melt-extruding each using a separate extruder and weighing each with a gear pump so that the weight ratio of A polymer and B polymer is 50:50, they are supplied to a spinning bag, and then A
It has a core-sheath composite shape so that the polymer is a sheath component and the B polymer is a core component, and is discharged from a nozzle heated at 285°C.
The spun yarn was collected at a winding speed of 1000 m/ms +1. Thereafter, the obtained spun yarn was drawn at a water bath temperature of 75° C., and then shrunk by 5% at a water bath temperature of 90° C. to obtain a drawn yarn. Then, it was mechanically crimped by a conventional method, and then a general oil was applied to it in an amount of Q, l wt%, and i
It was subjected to a relaxation heat treatment at oo° C. for 15 minutes, and then cut to a length of 51 to obtain raw cotton with a single yarn denier of 2.0.

After that, binder fiber with polyethylene terephthalate as the core component and copolymerized polyester as the sheath component (Kuraray Nfit N-720) 2-teal x 51III
After blending 20% of l, the basis weight is 100? / m" web was created and then subjected to hot air treatment to create a non-woven fabric, which was used as a base fabric for the pasting side. Processability from spinning to final non-woven fabric creation 1 was good and there were no problems.

On the surface of the non-woven fabric, a 5-strong oil solution of nodomethacin was applied together with other bases such as gelatin, titanium oxide, and glycerin, and a patch was prepared under conditions such that 70 η of indomethacin was applied to 1 weight of the non-woven fabric. . A leaving test was conducted with the female pattern pasted on the surface. Thereafter, the concentration of indomethacin applied was estimated from a calibration curve by measuring the absorption intensity at a wavelength of 319 nm in the ultraviolet absorption spectrum over time, and the remaining amount was measured. The results are shown in Table 1, and no decrease in the amount of the applied drug over time was observed. The efficacy of the patch was also tested on 10 men and women, and the medicinal efficacy was found to be good.

[Comparative Example 1] Polyethylene terephthalate fibers were spun and drawn in a conventional manner. After that, a raw cotton of 2 denier 51 fi was prepared using a conventional method, and after mixing 20 times of Kuraray's N-720 Pai 7f-RR2 denier x 51 fi into the polyester raw cotton, a web with a basis weight of 100 y/ni was made. After that, a nonwoven fabric was prepared by hot air treatment to form a patch layer base fabric.Then, the drug and base material were applied under the same conditions as in the example, and with release paper pasted on the surface. , a standing test was conducted.The results are shown in Table 1, and it was observed that the amount of the applied chemical decreased over time, and the chemical was absorbed into the fiber base fabric, making it impossible for the effective chemical to be applied on the coated surface. It was estimated that the amount decreased.Also, in actual use tests, it was observed that the medicinal efficacy decreased over time.

[Comparative Example 2] High-density polyethylene (Mitsubishi Kasei Yucalombard JX-10) was used as the A polymer, and polyethylene terephthalate with [η) of 0.60 was used as the -1B polymer.
Otherwise, raw cotton having a core-sheath composite shape was prepared in the same manner as in Example 1, in which polymer A was the sheath component and polymer B was the core component. Next, a web with a basis weight of 1009/m' was prepared, and then treated with hot air to form a nonwoven fabric, which was used as a patch layer base fabric.

Thereafter, under the same conditions as in Example 1, a chemical agent and a base were applied, and a leaving test was conducted with a female pattern pasted on the surface. The results are shown in Table 1, and it was observed that the amount of the applied drug decreased over time, which indicates that the amount of the drug applied to the fiber base fabric progressed and the effective amount of the drug on the coated surface decreased. was estimated. In addition, in actual use tests, the medicinal efficacy decreased over time. Number of people who recognized the effectiveness [Example 2.3] Example 1 except that in Example 2, the ethylene content of Polymer A was increased by 32 moles, and in Example 3, the ethylene content of Polymer A was increased by 48 moles. In both cases, no decrease in the amount of applied drug was observed over time.As for the efficacy of the patch, actual use tests showed that the medicinal efficacy was good. Ta.

[Example 4.5] Example 3 used polybutylene terephthalate (Mitsubishi Kasei Novedol 5008) & as the B polymer, and Example 4 used nylon 6 (Ube Industries No. 1013) as the B polymer.
BK) was carried out in the same manner as in Example 1, except that BK) was used. In either case, no decrease in the amount of the applied drug was observed over time. As for its effectiveness as a sweet patch, actual use tests showed that it had good medicinal efficacy.

[Examples 6 to 8] Tests were conducted by changing the cross-sectional shape. Example 6 has an eccentric core-sheath cross section shown in FIG. 6, Example 7 has a laminated shape shown in FIG. 8, and Example 8 has a ratio of one polymer A to one polymer B of 30.
The experiment was carried out using the same method as in Example 1, except that the cross-sectional shape of the pair 70 and the non-uniformly mixed state shown in FIG. 13 were used. In either case, no decrease in the amount of applied drug over time was observed.

In addition, as for the effect as a patch, actual use tests showed that the medicinal effect was good and there were no problems.

[Example 9] The same method as in Example 1 was carried out except that the ratio of polymer A to polymer B was 30:70. No decrease in the amount of applied drug over time was observed. In addition, as for its effectiveness as a patch, as a result of actual use tests,
The medicinal efficacy was good and there were no problems.

[Example 10] The same method as Example 1 was carried out except that ketoprofen was used as the drug. However, the remaining amount of applied ketoprofen was measured by measuring the wavelength of 2831 m in the ultraviolet absorption spectrum. No decrease in the amount of applied drug over time was observed. As for the effectiveness of the patch, the medicinal effects were good as a result of actual testing.

[Comparative Example 3] A polymer with an ethylene content of 20 moles was used as the A polymer, but the fluidity during melt spinning was poor and the spinnability was poor, so that it could not be made into fibers.

[Comparative Example 4] A polymer with an ethylene content of 80 moles was used as the A polymer, and the same method as in Example 1 was performed except for the following.

However, the performance with the adhesive patch was at the same level as Comparative Example 2, which was not preferable.

[Comparative Example 5] A polymer with a degree of saponification of 80 was used as the A polymer, and the same method as in Example 1 was carried out except that the polymer A had a saponification degree of 80. Problems with adhesion between single yarns occurred during the spinning and drawing processes, and a fiber structure worthy of evaluation could not be obtained.

The data and results for the above Examples and Comparative Examples are listed in Table 2.

(Effects of the Present Invention) As described above, the present invention provides a method for preparing two types of polymers, a saponified ethylene-vinyl acetate copolymer and a crystalline thermoplastic resin having a melting point of 150° C. or higher, which meet specific conditions. By spinning composite fibers into fibers and coating the fiber aggregate with vegetable oil containing dissolved non-steroidal analgesics and anti-inflammatory agents with excellent transdermal absorption, it can be stored for long periods of time. We have discovered a patch that has long-lasting medicinal effects.

[Brief explanation of drawings]

FIGS. 1 to 13 are examples of composite shapes of the fibers of the present invention. FIG. 14 is an example of a spinning apparatus for obtaining the fiber of the present invention.

Claims (2)

[Claims] (1) Ethylene content 25-70 mol%, saponification degree 9
5% or more saponified ethylene-vinyl acetate copolymer (A
polymer) and a crystalline thermoplastic polymer (B polymer) with a melting point of 150° C. or higher that has fiber-forming properties, and further contains 10% or more of composite fibers in which the A polymer accounts for 60% or more of the fiber circumference; A patch characterized by being coated with vegetable oil in which a non-steroidal transdermal analgesic and anti-inflammatory agent is dissolved and dispersed. (2) The non-steroidal transdermal analgesic and anti-inflammatory agent comprises one or more selected from ketoprofen, indomethacin, flurpiprofen, methyl salicylate, diclofenac, and ibuprofen menthol. patch.